Schuster David M, Nanni Cristina, Fanti Stefano, Oka Shuntaro, Okudaira Hiroyuki, Inoue Yusuke, Sörensen Jens, Owenius Rikard, Choyke Peter, Turkbey Baris, Bogsrud Trond V, Bach-Gansmo Tore, Halkar Raghuveer K, Nye Jonathon A, Odewole Oluwaseun A, Savir-Baruch Bital, Goodman Mark M
Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia
Department of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy.
J Nucl Med. 2014 Dec;55(12):1986-92. doi: 10.2967/jnumed.114.143628. Epub 2014 Nov 13.
Anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid ((18)F-FACBC) is a synthetic amino acid analog PET radiotracer undergoing clinical trials for the evaluation of prostate and other cancers. We aimed to describe common physiologic uptake patterns, incidental findings, and variants in patients who had undergone (18)F-FACBC PET.
Sixteen clinical trials involving 611 (18)F-FACBC studies from 6 centers, which included dosimetry studies on 12 healthy volunteers, were reviewed. Qualitative observations of common physiologic patterns, incidental uptake, and variants that could simulate disease were recorded and compared with similar observations in studies of the healthy volunteers. Quantitative analysis of select data and review of prior published reports and observations were also made.
The liver and pancreas demonstrated the most intense uptake. Moderate salivary and pituitary uptake and variable mild to moderate bowel activity were commonly visualized. Moderate bone marrow and mild muscle activity were present on early images, with marrow activity decreasing and muscle activity increasing with time. Brain and lungs demonstrated activity less than blood pool. Though (18)F-FACBC exhibited little renal excretion or bladder uptake during the clinically useful early imaging time window, mild to moderate activity might accumulate in the bladder and interfere with evaluation of adjacent prostate bed and seminal vesicles in 5%-10% of patients. Uptake might also occur from benign processes such as infection, inflammation, prostatic hyperplasia, and metabolically active benign bone lesions such as osteoid osteoma.
Common physiologic uptake patterns were similar to those noted in healthy volunteers. The activity in organs followed the presence of amino acid transport and metabolism described with other amino acid-based PET radiotracers. As with other PET radiotracers such as (18)F-FDG, focal nonphysiologic uptake may represent incidental malignancy. Uptake due to benign etiologies distinct from physiologic background also occurred and could lead to misinterpretations if the reader is unaware of them.
1-氨基-3-(18)F-氟环丁烷-1-羧酸((18)F-FACBC)是一种合成氨基酸类似物PET放射性示踪剂,正在进行用于评估前列腺癌和其他癌症的临床试验。我们旨在描述接受(18)F-FACBC PET检查的患者常见的生理摄取模式、偶然发现及变异情况。
回顾了16项临床试验,这些试验涉及来自6个中心的611例(18)F-FACBC研究,其中包括对12名健康志愿者的剂量学研究。记录了常见生理模式、偶然摄取及可能模拟疾病的变异情况的定性观察结果,并与健康志愿者研究中的类似观察结果进行比较。还对选定数据进行了定量分析,并查阅了先前发表的报告和观察结果。
肝脏和胰腺摄取最为强烈。通常可见中等程度的唾液腺和垂体摄取以及不同程度的轻度至中度肠道活性。早期图像上可见中等程度的骨髓活性和轻度肌肉活性,骨髓活性随时间降低,肌肉活性随时间增加。脑和肺的活性低于血池。虽然在临床上有用的早期成像时间窗内(18)F-FACBC很少经肾脏排泄或在膀胱摄取,但在5%-10%的患者中,轻度至中度活性可能会在膀胱中积聚并干扰对相邻前列腺床和精囊的评估。摄取也可能源于感染、炎症、前列腺增生等良性病变以及骨样骨瘤等代谢活跃的良性骨病变。
常见生理摄取模式与健康志愿者中观察到的模式相似。器官中的活性与其他基于氨基酸的PET放射性示踪剂所描述的氨基酸转运和代谢情况相符。与其他PET放射性示踪剂如(18)F-FDG一样,局灶性非生理性摄取可能代表偶然的恶性肿瘤。由不同于生理背景的良性病因导致的摄取也会发生,如果读者不了解这些情况,可能会导致误解。